First line immunochemotherapy with cisplatin-based protocol by intraperitoneal and intravenous routes in ovarian cancer: Technique and results of 82 cases

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 66, Issue 1, 1996, Pages 57-64

  Zylberberg, B ^a,c   Dormontd, D ^d   Antoine, J M ^c   Madelenat, P ^a   Ravina, J H ^c   Uzan, S ^c   Salat Baroux, J ^b  

^a BICHAT HOSPITAL   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c HÔPITAL TENON   (France)

^d INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

Author keywords

Immunotherapy; Intraperitoneal and intravenous chemotherapy; Ovarian carcinoma

Indexed keywords

BLEOMYCIN; CHOLERA TOXIN; CISPLATIN; CYTARABINE; DOXORUBICIN; FLUOROURACIL; IFOSFAMIDE; PACLITAXEL; SODIUM THIOSULFATE;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; IMMUNOTHERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; VIBRIO CHOLERAE;

EID: 0029874176     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/0301-2115(96)02386-X     Document Type: Article

References (38)

1. Decker DG, Thomas MD, Fleming TR, Malkasian GD. Cyclophosphamide plus Cis-platinium in combination : treatment program for stage III or IV ovarian carcinoma. Obstet Gynecol 1982; 60: 481-487.
2. Luesley DM, Lawton FG, Chan KK, Blackledge GR, Mould J. Second regard laparotomy. In: Ovarian cancer: the way ahead. Wiley Medical, Chameleon Press, London, 1987; 297-308.
3. Menczer J, Modan M, Brenner J, Ben Baruch G, Brenner H. Completion of cisplatinum based combination chemotherapy. Gynecol Oncol 1986; 24: 149-154.
4. Omura GA, Bundy BN, Berek JS, Curry S, Delgado G, Mortel R. Randomized trial of cyclophosphamide plus Cisplatin with or without doxorubicin in ovarian carcinoma gynecologic oncologic group study. J Clin Oncol 1989; 7: 457-465.
5. Ozols RF, Young RC. Chemotherapy of ovarian cancer. Semin Oncol 1991; 18: 222-232.
6. Neijt JP, Ten Bokkel Huinink WW, Van Der Burg M, Van Oosterom A, Willemse PHB, Heintz APM, Van Lent M, Trimbos JB, Bouma J, Vermorken J, Van Houwelingen J. Randomized trial comparing two combinations chemotherapy regimens (CHAP-S v CP) in advanced ovarian carcinoma. J Clin Oncol 1987; 5: 1157-1168.
7. Ozols RF. Ovarian cancer. Sem Surg Oncol 1990; 6: 328-338.
8. Thigpen TJ, Blessing JA, Vance RB, Lambuth BW Chemotherapy in ovarian cancer. Present role and future prospects. Sem Oncol 1989; 16: 58-65.
9. Berek JS, Hacker NP, Lichtenstein A, Jung T, Spina C, Knox RM, Brady J, Greene T, Ettinger LM, Lagasse LD, Bonnemen EM, Spiegel RJ and Zighelboim J. Intraperitoneal recombinant alpha 2-Interferon for salvage immunotherapy in persistent epithelial ovarian cancer. Cancer Treat Rev 1985; 12: 23-32.
10. Markman M. Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity. Cancer Treat Rev 1986; 13: 219-242.
11. Roboz J, Jacobs AJ, Holland TP, Deppe G, Cohen CJ. Intraperitoneal infusion of Doxorubucin in the treatment of gynecologic carcinomas. Med Pediatr Oncol 1981; 9: 245-250.
12. Rubin SC, Hoskins WJ, Hakes TB. Recurence after negative second regard laparotomy for ovarian cancer: analysis of risk factors. Am J Obstet Gynecol 1988; 159: 1094-1098.
13. Schwartz PE, Smith JP. Second regard operations in ovarian cancer. Am J Obstet Gynecol 1980; 138: 1124-1130.
14. Speyer JL, Myers CE. The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies. Recent Results Cancer Res 1980; 74: 264-269.
15. Dodin A, Zylberberg B. Cancer de l'ovaire: traitement par Neuraminidase spécifique. La Nouvelle Presse Med, 03.02.79; 8 (6).
16. Dodin A, Zylberberg B, Delorme L. Effets antitumoraux in vivo et in vitro d'un extrait de vibrio cholerae dans différents modèles murins. I. Effets in vivo d'un extrait bactérien de vibrio cholerae sur l'évolution de différentes greffes tumorales murines. CR Soc Biol 1992; 186: 394-400.
17. Delorme L, Dodin A, Zylberberg B. II. Effets antimuraux in vitro d'un extrait de vibrio cholerae: inhibition de la croissance des cellules 3 LL et stimulation des splenocytes murins. CR Soc Biol 1993; 116: 477-484.
18. Swenerton KD, Hislop TG, Spinelli J et al. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol 1985; 65: 264-270.
19. Omura GA, Brady MF, Homesley HD, Yordan E, Major FS, Buschbaum HJ, Park RC. Long-term following and prognostic factor analysis in advanced ovarian carcinoma: the gynecologic oncology group experience. J Clin Oncol July 1991; 9 (7): 1138-1150.
20. Roberts WS, Hodell K, Rich WM, Di Saia PJ. Second regard laparotomy in the management of gynecologic malignancy. Gynecol Oncol 1982; 13: 345-355.
21. Bereck JS, Hacker NF, Lagasse LD, Poth T, Resnick B, Nieberg RK. Second regard laparotomy in stage III epithelial ovarian cancer: clinical variables associated with disease status. Obstet Gynecol 1984; 64: 207-212.
22. Brenner DE, Shaf MI, Jones HW, Grosh WW, Greco A, Burnett LS. Abdomino pelvic computed tomography: evaluation in patients undergoing second regard laparotomy for ovarian carcinoma. Obstet Gynecol 1985; 65: 715.
23. Cohen CJ, Goldberg JE, Holland JF, Bruckner HW, Deppe G, Gusberg SB, Wallach RC, Kabakow B, Rodin J. Improved therapy with cisplatin regimens for patients with ovariancarcinoma (FIGO stages III and IV) as surgical and staging (second regard operation). Am J Obstet Gynecol 1983; 145: 955-967.
24. Ozols RF, Fisher RI, Anderson T, Makuch R, Young RC. Peritoneoscopy in the management of ovarian cancer. Am J Obstet Gynecol 1981; 140: 611-619.
25. Ozols RF, Myers CE, Young RC. Intraperitoneal chemotherapy. Ann Intern Med 1984; 101: 118-120.
26. Phillips PN, Bushbaum JH, Lifschiftz S. Reexploration after treatment of ovarian carcinoma. Gynecol Oncol 1979; 8: 339-345.
27. Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 1979; 39: 3209-3214.
28. Ozols RF. Intraperitoneal therapy in ovarian cancer: time's up. J Clin Oncol 1991; 9: 197-199.
29. Ozols RF, Young RC, Speyer JL, Sugerbaker PH, Green R, Jenkins J, Myers CE. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer 1982; 42: 4265-4269.
30. Litterst CL, Collins JM, Lowe MC, Arnold ST, Powell DM, Guariono AM. Local and systemic toxicity resulting from large volume i.p. administration of doxorubicin in the rat. Cancer Treat Rep 1982; 66: 157-161.
31. Markman M, Howell SB. Intraperitoneal chemotherapy for ovarian carcinoma. In: Alberts DS, Surwit EA, editors. Ovarian Cancer. Boston: Martinus Nijhoff, 1985; 179-212.
32. West GW, Weichselbau R, Little JB. Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res 1980; 40: 3668.
33. Mc Vie JG, Dikhoff TGMH, Van der Heide J, Dubelman R, Tenbokkel Huinink W. Tissue concentration of platinium after Intraperitoneal cisplatin administration in patients. Proc Am Assoc Cancer Res 1985; 26: 162.
34. Berek JS, Knapp RC, Hacker NF, Lichtenstein A, Jung T, Spina C, Obrist R, Griffiths CT, Berkowitz RS, Parker L, Zigelboim J, Bast RC. Intraperitoneal immunotherapy of epithelial ovarian carcinom with corynebacterum parvum. Am J Obstet Gynecol 1985; 152: 1003.
35. Berek JS, Hacker NF, Lichtenstein A. Intraperitoneal recombinant alpha-interferon for 'salvage' immunotherapy in stage III epithelial ovarian cancer: a gynecologic oncology group study. Cancer Res 1985; 45: 4447.
36. Howell SB. Intraperitoneal chemotherapy: the use of concurrent systemic neutralizing agents. Semin Oncol September 1985; 12, 3 (Suppl 4): 17-22.
37. Markman M. Intraperitoneal chemotherapy as treatment of ovarian cancer: why, how and when. Obstet Gynecol Survey 1987; 42 (9): 533-539.
38. Piccart MJ, Speyer JL, Markman M, Tenbokkel Huinink WW, Alberts D, Jenkins J, Muggia F. Intraperitoneal chemotherapy: technical experiences at five institutions. Semin Oncol 1985; 14, 5 (Suppl 4): 90-96.